Autologous cell–based therapy for male and female pattern hair loss using dermal sheath cup cells: A randomized placebo-controlled double-blinded dose-finding clinical study - 19/06/20
, Shiro Niiyama, MD, PhD b, Ryokichi Irisawa, MD a, Kazutoshi Harada, MD, PhD a, Yosuke Nakazawa, PhD c, Jiro Kishimoto, PhD cAbstract |
Background |
Few effective treatments are available for male pattern hair loss (MPHL) or, especially, for female pattern hair loss (FPHL). Recently, cell-based therapies using autologous or allogeneic cells have been used clinically.
Objective |
We examined the safety and efficacy of autologous cell–based therapy using dermal sheath cup (DSC) cells to treat MPHL and FPHL.
Methods |
DSCs dissected from occipital hair follicles were cultured to manufacture DSC cells. Participants with MPHL or FPHL received single injections of 7.5 × 106, 1.5 × 106, or 3.0 × 105 DSC cells or a placebo in 4 randomized separate regions on the scalp, and hair densities and diameters were measured for 3, 6, 9, and 12 months.
Results |
Fifty men and 15 women aged 33 to 64 years were injected with DSC cells. Total hair density and cumulative hair diameter at the 3.0 × 105 DSC cells injection site was significantly increased compared with the placebo after 6 and 9 months. Men and women showed similar improvements, and there were no serious adverse events.
Limitations |
No lower cell numbers were tested, and the positive effect was temporary until 9 months.
Conclusion |
The results suggest that cell therapy with autologous DSC cells may be useful as a new therapeutic method for treating MPHL and FPHL.
Le texte complet de cet article est disponible en PDF.Key words : dermal sheath cup cells, cell-based therapy, regenerative medicine, hair regrowth, male pattern hair loss, female pattern hair loss, androgenetic alopecia
Abbreviations used : ALP, DP, DSC, FPHL, MPHL, PHL
Plan
| Funding sources: Supported by Shiseido Co., Ltd., Japan |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Reviewed and approved by the Tokyo Medical University Hospital IRB (approval no. 115), the Toho University Ohashi Medical Center IRB (approval no. 14-44), and the Certified Committee for Regenerative Medicine at Tokyo Medical University (approval no. 2016001). |
Vol 83 - N° 1
P. 109-116 - juillet 2020 Retour au numéro
Article précédent
- Simplifying contraception requirements for iPLEDGE: A decision analysis
- John S. Barbieri, Andrea H. Roe, Arash Mostaghimi
- Malignancy in dermatomyositis: A retrospective study of 201 patients seen at the University of Pennsylvania
- Kimberly Bowerman, David R. Pearson, Joyce Okawa, Victoria P. Werth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?